Program
TPX-115
A development code. Also written as “TPX-115(allogeneic fibroblasts)”.
Its studies are mostly in Rotator Cuff Injuries, led by Tego Science.
Furthest: phase 3, since May 10, 20244 company-led studies, 3 open or runningNext primary completion: May 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Tego Science | 43 open or running | phase 3since May 10, 2024 | Jul 3, 2020 | May 2027phase 2 · NCT07219654 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 3, 2020First study: phase 2 study in Rotator Cuff InjuriesFirst studyNCT04470167 · 49 enrolled · Korea, Republic of
- May 10, 2024Phase 3 study in Partial Thickness Rotator Cuff TearNCT06414005 · 166 planned · Korea, Republic of
- Jul 29, 2024Phase 1 study in Nasolabial Fold, HypoplasticNCT06533540 · 18 enrolled · South Korea
- Oct 20, 2025Phase 2 study in Partial Thickness Rotator Cuff TearsNCT07219654 · 60 planned · United States
Ahead
- May 2027Primary completion: phase 2 study in Partial Thickness Rotator Cuff TearsNCT07219654
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07219654Partial Thickness Rotator Cuff Tears · United States | 2 | Recruiting | May 2027 | 60 |
| NCT06533540Nasolabial Fold, Hypoplastic · South Korea | 1 | Active, not recruiting | Mar 2026 | 18 |
| NCT06414005Partial Thickness Rotator Cuff Tear · Korea, Republic of | 3 | Recruiting | Jun 30, 2026 | 166 |
| NCT04470167Rotator Cuff Injuries · Korea, Republic of | 2 | Completed | Feb 17, 2022 | 49 |
How it is read
Names in the registry
- “TPX-115”, 3 entries
- “TPX-115(allogeneic fibroblasts)”, 1 entry
Codes read as this program: TPX115.
Conditions, from the studies’ own filings
- Rotator Cuff Injuries, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.